DE60142712D1 - Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen - Google Patents

Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen

Info

Publication number
DE60142712D1
DE60142712D1 DE60142712T DE60142712T DE60142712D1 DE 60142712 D1 DE60142712 D1 DE 60142712D1 DE 60142712 T DE60142712 T DE 60142712T DE 60142712 T DE60142712 T DE 60142712T DE 60142712 D1 DE60142712 D1 DE 60142712D1
Authority
DE
Germany
Prior art keywords
botulinum toxin
treat seizure
seizure pain
pain
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142712T
Other languages
English (en)
Inventor
Kei Roger Aoki
Minglei Cui
Stephen Jenkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24196890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60142712(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60142712D1 publication Critical patent/DE60142712D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60142712T 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen Expired - Lifetime DE60142712D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/550,371 US6464986B1 (en) 2000-04-14 2000-04-14 Method for treating pain by peripheral administration of a neurotoxin

Publications (1)

Publication Number Publication Date
DE60142712D1 true DE60142712D1 (de) 2010-09-09

Family

ID=24196890

Family Applications (6)

Application Number Title Priority Date Filing Date
DE60143549T Expired - Lifetime DE60143549D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von durch Infektion verursachtem Schmerz
DE60142590T Expired - Lifetime DE60142590D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE60143061T Expired - Lifetime DE60143061D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen
DE60128899T Revoked DE60128899T2 (de) 2000-04-14 2001-04-11 Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen
DE60142712T Expired - Lifetime DE60142712D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen
DE60141230T Expired - Lifetime DE60141230D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE60143549T Expired - Lifetime DE60143549D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von durch Infektion verursachtem Schmerz
DE60142590T Expired - Lifetime DE60142590D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE60143061T Expired - Lifetime DE60143061D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen
DE60128899T Revoked DE60128899T2 (de) 2000-04-14 2001-04-11 Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60141230T Expired - Lifetime DE60141230D1 (de) 2000-04-14 2001-04-11 Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen

Country Status (19)

Country Link
US (14) US6464986B1 (de)
EP (7) EP1272207B1 (de)
JP (1) JP4037652B2 (de)
KR (1) KR20030009431A (de)
CN (1) CN1188165C (de)
AR (1) AR030209A1 (de)
AT (6) ATE475427T1 (de)
AU (2) AU2001251546B9 (de)
BR (1) BR0110030A (de)
CA (3) CA2485919A1 (de)
CY (2) CY1108065T1 (de)
DE (6) DE60143549D1 (de)
DK (6) DK1604681T3 (de)
ES (7) ES2353878T3 (de)
MX (1) MXPA02009932A (de)
NZ (1) NZ521535A (de)
PT (2) PT1272207E (de)
TW (1) TWI282282B (de)
WO (1) WO2001078760A2 (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6977080B1 (en) 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
EP1365800B1 (de) * 2000-06-28 2013-03-06 Ira Sanders Methoden zur verwendung von tetanustoxin zur therapeutischen anwendung bei lebewesen (säugetieren)
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US20030100574A1 (en) 2001-11-15 2003-05-29 Wilson Nestor Antonio Lagos Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7964644B2 (en) * 2002-07-19 2011-06-21 Mestex Ag Use of neurotoxic substances for the production of a means for the treatment of joint paint and method for application of said means
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
JP2007528351A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 慢性の霰粒腫および麦粒腫のボツリヌス毒素による治療
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
EP1599221B1 (de) * 2003-03-06 2011-12-28 Botulinum Toxin Research Associates, Inc. Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7354740B2 (en) 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
CN1997373B (zh) * 2004-05-07 2010-12-22 菲特托克斯有限公司 藻毒素及其用途
KR100668570B1 (ko) 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
ES2555856T3 (es) 2004-09-23 2016-01-11 Toxcure, Inc. Tratamiento de neoplasmas con neurotoxina
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
JP2008532549A (ja) 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
ES2351942T3 (es) 2005-04-05 2011-02-14 Allergan Inc Analisis de la actividad de una toxina clostridial.
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
EP2248534A1 (de) * 2005-06-14 2010-11-10 Botulinum Toxin Research Associates, Inc. Botulinumtoxin und die Behandlung von primären Stimmungs- und Affektivenstörungen
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8105611B2 (en) 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
BRPI0613631A8 (pt) * 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US8318181B2 (en) 2005-12-01 2012-11-27 University Of Massachusetts Lowell Botulinum nanoemulsions
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
KR101518077B1 (ko) 2006-12-01 2015-05-28 안테리오스, 인코퍼레이티드 펩티드 나노입자 및 이의 용도
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
JP2010519211A (ja) 2007-02-15 2010-06-03 アラーガン、インコーポレイテッド 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
ES2660906T3 (es) 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
DE102007038015A1 (de) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verwendung eines Neurotoxins
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
WO2010016895A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
WO2010016901A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100112006A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 kD)
EP2403522B1 (de) 2009-03-06 2015-12-16 Allergan, Inc. Clostridium-toxin zur verbesserung des ejakulats
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
US20110184337A1 (en) 2010-01-26 2011-07-28 Evans Michael A Methods and devices for denervation
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
US20120195878A1 (en) 2011-01-28 2012-08-02 Allergan, Inc. Protocol for the administration of botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
US20140140983A1 (en) 2011-07-08 2014-05-22 Allergan, Inc. Method for treatment of autonomic nervous system disorders
JP6092205B2 (ja) 2011-07-14 2017-03-08 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 性的行為に関連した失禁の治療方法
KR20140082956A (ko) 2011-07-20 2014-07-03 알러간, 인코포레이티드 지방 침착물의 치료방법에 이용하기 위한 보툴리눔 독소
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
US10035820B2 (en) 2012-04-13 2018-07-31 Lubrizol Advanced Materials, Inc Compounds which inhibit neuronal exocytosis
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
CN105451710A (zh) 2013-03-22 2016-03-30 利普泰股份公司 用于治疗和/或护理皮肤、粘膜和/或指甲的外泌多糖
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
AU2015315571A1 (en) * 2014-09-12 2017-04-27 Allergan, Inc. Methods for treating osteoarthritis pain
DK3242884T3 (da) 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
JP7097070B2 (ja) * 2015-10-01 2022-07-07 ゴレイニ インコーポレイテッド クロライドチャネルの標的発現及びその使用方法
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
US11623000B2 (en) 2017-05-24 2023-04-11 Atgc Co., Ltd. Pharmaceutical composition for treating foot pain disease including botulinum toxin and hyaluronic acid, and foot pain disease treatment method using same
EP3470054B1 (de) 2017-10-11 2023-09-20 Hugel Inc. Mikrostrukturformulierungstechniken für botulinumtoxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
EP3660509B1 (de) 2018-11-29 2022-03-09 Hugel Inc. Zellbasiertes verfahren zur bestimmung der aktivität von botulinumtoxin
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693207B1 (fr) * 1992-07-03 1994-09-30 Orsan Souche de levure permettant la co-expression d'une activité mono-oxygénase de cytochrome P450 hétérologue et d'une NADPH-cytochrome P450-réductase endogène ou hétérologue et son utilisation à des fins de bioconversion.
JP4381477B2 (ja) 1993-01-15 2009-12-09 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド 筋膜疼痛症候群の治療方法
US5592212A (en) * 1993-04-16 1997-01-07 News Datacom Ltd. Methods and systems for non-program applications for subscriber television
ES2319860T3 (es) * 1993-12-28 2009-05-14 Allergan, Inc. Uso de toxina botulinica de tipo b para la fabricacion de un medicamento para reducir el dolor asociado a un trastorno muscular.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JPH08306853A (ja) * 1995-05-09 1996-11-22 Fujitsu Ltd 半導体装置及びその製造方法及びリードフレームの製造方法
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2006017004A1 (en) 2004-07-07 2006-02-16 Obstecare Inc. Method for monitoring a childbirth process

Also Published As

Publication number Publication date
US20040018214A1 (en) 2004-01-29
EP1604680A1 (de) 2005-12-14
EP1272207B1 (de) 2007-06-13
CA2485919A1 (en) 2001-10-25
MXPA02009932A (es) 2004-08-19
EP1576963A2 (de) 2005-09-21
US20040018213A1 (en) 2004-01-29
US7468189B2 (en) 2008-12-23
US20080138364A1 (en) 2008-06-12
ATE364393T1 (de) 2007-07-15
JP4037652B2 (ja) 2008-01-23
DK1604680T3 (da) 2010-05-10
DK1604678T3 (da) 2010-10-18
EP1604678B1 (de) 2010-07-14
ES2287117T3 (es) 2007-12-16
CA2406367C (en) 2008-01-29
US7211262B2 (en) 2007-05-01
DE60128899D1 (de) 2007-07-26
EP1604679A1 (de) 2005-12-14
ATE456375T1 (de) 2010-02-15
EP1576963A3 (de) 2005-12-07
ES2394314T3 (es) 2013-01-30
DE60141230D1 (de) 2010-03-18
ATE480253T1 (de) 2010-09-15
DE60142590D1 (de) 2010-08-26
US20060039916A1 (en) 2006-02-23
US20050058666A1 (en) 2005-03-17
US20040018212A1 (en) 2004-01-29
DK1272207T3 (da) 2007-09-10
US7294339B2 (en) 2007-11-13
EP1604681A1 (de) 2005-12-14
DK1576963T3 (da) 2011-02-21
EP1604678A1 (de) 2005-12-14
NZ521535A (en) 2004-09-24
US7288260B2 (en) 2007-10-30
DE60143549D1 (de) 2011-01-05
EP1604680B1 (de) 2010-01-27
ATE475427T1 (de) 2010-08-15
AU5154601A (en) 2001-10-30
US20040028706A1 (en) 2004-02-12
CY1109972T1 (el) 2014-09-10
US7276245B2 (en) 2007-10-02
DK1604679T3 (da) 2010-10-25
TWI282282B (en) 2007-06-11
BR0110030A (pt) 2003-06-03
KR20030009431A (ko) 2003-01-29
US20060039917A1 (en) 2006-02-23
EP1550456B1 (de) 2012-09-26
ES2338238T3 (es) 2010-05-05
ES2353878T3 (es) 2011-03-07
US20060275326A1 (en) 2006-12-07
DK1604681T3 (da) 2010-11-29
US7374769B2 (en) 2008-05-20
US20070014816A1 (en) 2007-01-18
US6869610B2 (en) 2005-03-22
US7067137B2 (en) 2006-06-27
AU2001251546B9 (en) 2004-12-02
AU2001251546B2 (en) 2004-07-01
EP1604681B1 (de) 2010-09-08
EP1604679B1 (de) 2010-07-28
EP1272207A2 (de) 2003-01-08
CN1436085A (zh) 2003-08-13
US7172763B2 (en) 2007-02-06
EP1576963B1 (de) 2010-11-24
ES2347792T3 (es) 2010-11-04
US20050152925A1 (en) 2005-07-14
DE60143061D1 (de) 2010-10-21
AR030209A1 (es) 2003-08-13
US7291344B2 (en) 2007-11-06
WO2001078760A3 (en) 2002-03-21
DE60128899T2 (de) 2008-02-21
JP2003531127A (ja) 2003-10-21
US7361358B2 (en) 2008-04-22
WO2001078760A2 (en) 2001-10-25
CA2406367A1 (en) 2001-10-25
PT1604680E (pt) 2010-02-11
CN1188165C (zh) 2005-02-09
ES2349782T3 (es) 2011-01-11
US6464986B1 (en) 2002-10-15
ATE489102T1 (de) 2010-12-15
CA2485920A1 (en) 2001-10-25
EP1550456A2 (de) 2005-07-06
US20060275325A1 (en) 2006-12-07
ATE473753T1 (de) 2010-07-15
US20020176872A1 (en) 2002-11-28
ES2347256T3 (es) 2010-10-27
CY1108065T1 (el) 2014-02-12
PT1272207E (pt) 2007-06-29
EP1550456A3 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
DE60142712D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen
ATE257013T1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE245032T1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE69434008D1 (de) Botulinustoxin zur Behandlung Muskelkrankheiten verbundenen Schmerzen
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
ATE526982T1 (de) Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
ATE281167T1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
ATE232378T1 (de) Reinigungspflaster zur verbesserung des hautzustandes
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
ATE493145T1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60103685D1 (de) Behandlung von Poriomania
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
ATE267608T1 (de) Verwendung von fsh zur behandlung von infertilität